Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use B UPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for B UPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE AND NALOXONE sublingual tablets, CIII Initial U.S. Approval: 2002
Medication labelWhy this: Advisory · dailymed-prescription
Buprenorphine and Naloxone Sublingual Tablets are indicated for the maintenance treatment of opioid dependence. Buprenorphine and Naloxone Sublingual Tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support.
- generic_name
- buprenorphine and naloxone
- product_names
- Buprenorphine and Naloxone
- ndc
- 63629-5074, 63629-7269, 65162-415, 63629-5074-1, 63629-5074-2, 63629-5074-3, 63629-5074-4, 63629-5074-5, 63629-5074-6, 63629-5074-7, 63629-5074-8, 63629-5074-9, 63629-5074-0, 65162-416, 63629-7269-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en